Strand Diagnostics, developer of the know error system, appointed Laura Beggrow as President. Beggrow previously served as Vice President of U.S. Sales and Marketing at Genomic Health, where she brought Oncotype DX products to the breast and colon cancer markets and increased sales from $10 million to more than $200 million per year.
“We expect that her experience in building out large-scale sales organizations, and her track record of driving growth in early-stage molecular diagnostics companies will help accelerate adoption of the know error system as the new standard of care,” said Strand Diagnostics CEO, Ted Schenberg, in the press release.
“Specimen provenance is an under-appreciated aspect of the diagnostic cycle, with as many as 3.5 percent of biopsies in certain clinical settings resulting in a diagnosis complicated by undetected specimen switches or contaminations,” added Beggrow, in the press release. “I look forward to working with this talented and dedicated team to eliminate diagnostic mistakes due to undetected provenance errors.”
The know error system is designed to prevent laboratory testing errors using DNA sampling. For a more detailed look at the know error system, click here for ImagingBIz’s previous coverage.